TITLE

Baclofen for maintenance treatment of opioid dependence: A randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]

AUTHOR(S)
Assadi, Seyed Mohammad; Radgoodarzi, Reza; Ahmadi-Abhari, Seyed Ali
PUB. DATE
January 2003
SOURCE
BMC Psychiatry;2003, Vol. 3, p16
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Results of preclinical studies suggest that the GABAB receptor agonist baclofen may be useful in treatment of opioid dependence. This study was aimed at assessing the possible efficacy of baclofen for maintenance treatment of opioid dependence. Methods: A total of 40 opioid-dependent patients were detoxified and randomly assigned to receive baclofen (60 mg/day) or placebo in a 12-week, double blind, parallel-group trial. Primary outcome measure was retention in treatment. Secondary outcome measures included opioids and alcohol use according to urinalysis and self-report ratings, intensity of opioid craving assessed with a visual analogue scale, opioid withdrawal symptoms as measured by the Short Opiate Withdrawal Scale and depression scores on the Hamilton inventory. Results: Treatment retention was significantly higher in the baclofen group. Baclofen also showed a significant superiority over placebo in terms of opiate withdrawal syndrome and depressive symptoms. Non-significant, but generally favorable responses were seen in the baclofen group with other outcome measures including intensity of opioid craving and self-reported opioid and alcohol use. However, no significant difference was seen in the rates of opioid-positive urine tests. Additionally, the drug side effects of the two groups were not significantly different. Conclusion: The results support further study of baclofen in the maintenance treatment of opioid dependence.
ACCESSION #
29323636

 

Related Articles

  • Saccharomyces boulardii for the Prevention of Antibiotic-Associated Diarrhea in Adult Hospitalized Patients: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial. Pozzoni, Pietro; Riva, Alessia; Bellatorre, Alessandro Giacco; Amigoni, Maria; Redaelli, Elena; Ronchetti, Anna; Stefani, Mariangela; Tironi, Rosangela; Molteni, Edoardo Ennio; Conte, Dario; Casazza, Giovanni; Colli, Agostino // American Journal of Gastroenterology;Jun2012, Vol. 107 Issue 6, p922 

    OBJECTIVES:Antibiotic-associated diarrhea (AAD) and Clostridium difficile-associated diarrhea (CDAD) are common complications of antibiotic use. Probiotics were effective in preventing AAD and CDAD in several randomized controlled trials. This study was aimed at testing the effect of...

  • Titan reports positive results from Phase III opioid addiction trial.  // PharmaWatch: Biotechnology;Sep2008, Vol. 7 Issue 9, p9 

    The article reports on the positive interim results of the phase III randomized, double-blind trial for the opioid addiction drug Probuphine, manufactured by Titan Pharmaceuticals Inc. Probuphine is a subcutaneous implant formulation which aims to treat opioid addiction. The trial reveals...

  • Dianicline, a Novel α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, for Smoking Cessation: A Randomized Placebo-Controlled Clinical Trial. Tonstad, Serena; Holme, Ingar; Tønnesen, Philip // Nicotine & Tobacco Research;Jan2011, Vol. 13 Issue 1, p1 

    Introduction: Dianicline is a α4β2 nicotinic acetylcholine receptor partial agonist, a class of drugs that includes varenicline and cytisine. Varenicline is efficacious for smoking cessation, while cytisine has not been studied systematically. The efficacy of dianicline has not been...

  • THE DEPRESSING NEWS ABOUT ANTIDEPRESSANTS. Begley, Sharon; Kliff, Sarah // Newsweek (Pacific Edition);2/8/2010 (Pacific Edition), Vol. 155 Issue 6, p36 

    This article discusses the efficacy of antidepressants. The author refers to research published in 1998 which found that antidepressants are effective in about three-quarters of the people tested. A second study which found that those given a placebo improved by approximately 75 percent as much...

  • THE DEPRESSING NEWS ABOUT ANTIDEPRESSANTS. Begley, Sharon; Kliff, Sarah // Newsweek;2/8/2010, Vol. 155 Issue 6, p34 

    This article discusses the efficacy of antidepressants. The author references a research study published in 1998 which found that antidepressants are effective in about three quarters of people with depression, but notes a second study which found that those given a placebo improved by...

  • THE DEPRESSING NEWS ABOUT ANTIDEPRESSANTS. Begley, Sharon; Kliff, Sarah // Newsweek (Atlantic Edition);2/8/2010 (Atlantic Edition), Vol. 155 Issue 6, p38 

    This article discusses the efficacy of antidepressants. The author refers to research published in 1998 which found that antidepressants are effective in about three-quarters of the people tested. A second study which found that those given a placebo improved by approximately 75 percent as much...

  • Review: methadone increases retention and reduces heroin use compared with non-pharmacological maintenance.  // Evidence Based Mental Health;Feb2010, Vol. 13 Issue 1, p26 

    The article discusses the study which investigates the effect of methadone maintenance treatment (MMT) to increase retention and reduce opioid dependence compare to non-pharmacologic maintenance. The study conducts independently selected and quality assessed randomized controlled trials of MMT...

  • Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial. Shaheen, Nicholas J.; Denison, Hans; Björck, Karin; Karlsson, Maria; Silberg, Debra G. // Gut;Sep2013, Vol. 62 Issue 9, p1248 

    Objective Lesogaberan (AZD3355) is a novel ɣ- aminobutyric acid B-type receptor agonist designed to treat gastro-oesophageal reflux disease (GERD) by inhibiting transient lower oesophageal sphincter relaxations. A randomised, double-blind, placebocontrolled, multi-centre phase IIb study was...

  • Evaluation of Anti-Hyperalgesic and Analgesic Effects of Two Benzodiazepines in Human Experimental Pain: A Randomized Placebo-Controlled Study. Vuilleumier, Pascal H.; Besson, Marie; Desmeules, Jules; Arendt-Nielsen, Lars; Curatolo, Michele // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Background and Aims: Compounds that act on GABA-receptors produce anti-hyperalgesia in animal models, but little is known on their effects in humans. The aim of this study was to explore the potential usefulness of GABA-agonism for the control of pain in humans. Two agonists at the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics